Advanced Cell Technology to Participate at the CIRM's Roundtable Discussion on Industry & Stem Cells in California.ALAMEDA, Calif. -- Michael D. West Dr. Michael D. West is an entrepreneurial scientist and visionary [1] [2] [3] [4] who has led progress in anti-aging and biotechnology. He is CEO of BioTime, Inc. , Chairman, President and Chief Scientific Officer of Advanced Cell Technology, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ACTC ACTC Apple Certified Technical Coordinator ACTC Almaden Cycle Touring Club ACTC Associated Colleges of the Twin Cities ACTC All Ceylon Tamil Congress (Sri Lanka) ACTC Association Canadienne de Télévision par Câble ), will participate at the California Institute of Regenerative Medicine's (CIRM CIRM Certified in Integrated Resource Management CIRM California Institute for Regenerative Medicine CIRM Comité International Radio-Maritime (International Radio-Medical Center) CIRM Corporate Infrastructure Resource Management ) Roundtable Discussion on Industry and Stem Cells stem cells, unspecialized human or animal cells that can produce mature specialized body cells and at the same time replicate themselves. Embryonic stem cells are derived from a blastocyst (the blastula typical of placental mammals; see embryo), which is very young in California: Fostering R & D, on Tuesday, July 25, 2006. CIRM is the state agency responsible for disbursing $3 billion for stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. research to California's universities and research institutions. The discussion is part of the CIRM's scientific strategic planning process and will begin at 1:00 p.m. at the Robertson Auditorium, Mission Bay Conference Center at UCSF UCSF University of California at San Francisco , San Francisco, CA. "We are enthusiastic supporters of Governor Schwarzenegger's decision to advance regenerative medicine," said Michael D. West, Chairman, President, and Chief Scientific Officer of Advanced Cell Technology. "We look forward to helping communicate the needs of the biotechnology industry to CIRM and identifying means to accelerate the translation of this important science into lifesaving therapy." About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell Embryonic stem cells (ES cells) are stem cells derived from the inner cell mass of an early stage embryo known as a blastocyst. Human embryos reach the blastocyst stage 4-5 days post fertilization, at which time they consist of 50-150 cells. ES cells are pluripotent. technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com. Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2006. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion